Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.00.

Several analysts have issued reports on IPSC shares. Chardan Capital lowered their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Piper Sandler lowered their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research report on Monday, December 30th.

Century Therapeutics Stock Performance

IPSC opened at $0.77 on Friday. The firm has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.33. The company has a market cap of $65.32 million, a PE ratio of -0.42 and a beta of 1.73. Century Therapeutics has a 1 year low of $0.68 and a 1 year high of $5.51.

Institutional Trading of Century Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Century Therapeutics during the third quarter worth $27,000. State Street Corp lifted its stake in Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after buying an additional 57,323 shares during the last quarter. Wellington Management Group LLP bought a new stake in Century Therapeutics in the third quarter valued at $284,000. Barclays PLC lifted its stake in Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after buying an additional 45,797 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Century Therapeutics by 3.5% in the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after buying an additional 32,614 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.